This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the potential of UPLIZNA (inebilizumab-cdon), an anti-CD19 mAb, for patients with generalized Myasthenia Gravis and the publicly available results from the Phase 3 MINT trial
Ticker(s): AMGNWho's the expert?
Institution: Good Samaritan Hospital
- General neurologist at Good Samaritan Hospital
- Former neuroumuscular specialist at an academic center until 2018
- Sees approximately 50 myasthenia gravis patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
